We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Panacea Acquisition Corp | NYSE:NUVB | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.06 | -2.26% | 2.60 | 2.735 | 2.565 | 2.68 | 2,155,127 | 00:58:30 |
From Jan 2024 to Jan 2025
By Dean Seal
Nuvation Bio said federal regulators have cleared an investigational new drug application for its treatment of advanced solid tumors, NUV-1511.
The biopharmaceutical company said Monday that the Food and Drug Administration's clearance makes NUV-1511 the first clinical candidate from the company's novel drug-drug conjugate platform.
"This IND clearance expands our clinical pipeline and validates the approach of our proprietary DDC platform to design potent oncology-focused chimeric small molecules which combine tumor-targeting specificity with the anti-cancer activity of known oncology agents," Chief Executive David Hung said.
The company said it expects to launch a Phase 1/2 study of NUV-1511 in the first half of this year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 08, 2024 16:43 ET (21:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Panacea Acquisition Chart |
1 Month Panacea Acquisition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
